Australia's most trusted
source of pharma news
Wednesday, 02 July 2025
Posted 25 October 2021 AM
Specialised Therapeutics (ST) has struck a deal with Incyte Biosciences, the Swiss-based affiliate of Incyte to launch two new cancer therapies in three jurisdictions, including Australia.
Under the terms of the agreement, ST will be responsible for regulatory, distribution and local marketing related activities for tafasitamab (sold as Monjuvi in the US and Minjuvi in Europe) and Pemazyre in Australia, New Zealand and Singapore.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.